[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mechanically-ventilated-icu-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mechanically-ventilated-icu-patients":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,68,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100580054","stimulation-to-activate-respiration-100580054",false,"NCT06832306","STimulation to Activate RespIration","A Clinical Study Evaluating Temporary Transvenous Diaphragm Neurostimulation in Mechanically Ventilated Patients With Acute Hypoxemic Respiratory Failure","STARI","Inclusion Criteria:\n\n1. Male or female, 18 years or older, and\n2. Able to provide informed consent or have a legally authorized representative (LAR) \u002F Substitute Decision Maker (SDM) who can provide consent, and\n3. Have acute onset of new respiratory symptoms or dysfunction within the 2 weeks before onset of need for respiratory support, and\n4. Have arterial hypoxemia defined by one of:\n\n   * PaO2:FiO2 ratio ≤300 mm Hg on PEEP ≥5 cm H2O, or\n   * In the absence of an available arterial blood gas, SpO2 ≤97% on FiO2 ≥0.5 and PEEP ≥5 cm H2O with reliable SpO2 trace for the 2 hours immediately preceding eligibility assessment (this correlates to an upper limit of SpO2:FiO2 ratio of 316%) or\n   * Are receiving pulmonary vasodilators for acute hypoxemia, or\n   * Are being ventilated in the prone position for acute hypoxemia, and\n5. Have been mechanically ventilated for AHRF in the ICU for \\\u003C96 hours at the time of enrolment, and\n6. Are expected to require invasive mechanical ventilation ≥48 hours after enrollment in the opinion of the treating clinician\n\nExclusion Criteria:\n\n1. Hypoxemia is primarily attributable to acute exacerbation of chronic obstructive pulmonary disease, status asthmaticus, cardiogenic pulmonary edema, or pulmonary embolism.\n2. Underlying chronic parenchymal lung disease that may make recovery\u002Fextubation a challenge (e.g., COPD, pulmonary fibrosis).\n3. Broncho-pleural fistula at the time of eligibility assessment.\n4. Require extracorporeal membrane oxygenation.\n5. Pre-existing neurological, neuromuscular or muscular disorder or known phrenic nerve injury that could affect the respiratory muscles.\n6. BMI \\>70 kg\u002Fm2.\n7. Contraindications to left internal jugular vein or left subclavian vein catheterization (e.g., infection at the access site, known central venous stenosis, septic thrombophlebitis, left internal jugular ECMO cannula in situ, poor target vessels).\n8. Patient expected to transition to fully palliative care within 72 hours of enrollment.\n9. Chronic severe liver disease (e.g., Child-Pugh Score ≥10)\n10. Treating clinician deems enrollment not clinically appropriate.\n11. Currently enrolled in any other study of an investigational drug or device, which may affect the outcomes of the current study.\n12. Any electrical device (implanted or external) that may be prone to interaction with or interference from the AeroNova System, including neurological pacing\u002Fstimulator devices and cardiac pacemakers and defibrillators.\n13. Known or suspected to be pregnant or lactating.","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).",[27,28,29],"ARDS (Moderate or Severe)","AHRF","Mechanically Ventilated ICU Patients","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2025-05-28",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"Lungpacer Medical Inc.","INDUSTRY",7,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100643773","phase-4-the-effect-of-doxapram-on-diaphragmatic-excursionde-during-weaning-from-mechanical-ventilation-100643773","NCT07637149","the Effect of Doxapram on Diaphragmatic Excursion(DE) During Weaning From Mechanical Ventilation.","the Effect of Doxapram on Diaphragmatic Excursion(DE) During Weaning From Mechanical Ventilation :a Randomized Double Blinded Study.","Inclusion Criteria:\n\n* Adults (≥18 years) on mechanical ventilation for \\>48 hours.\n* Deemed ready for weaning by the clinical team: Defined as RSBI \\\u003C105, P\u002FF ratio \\>200, hemodynamic stability.\n* Stable hemodynamics and adequate oxygenation (PaO₂\u002FFiO₂ \\>150)\n\nExclusion Criteria:\n\n* Severe neurological impairment :Defined as GCS ≤8 or spinal cord injury above T5 .\n\n  * Known hypersensitivity to doxapram.\n  * Pregnancy or lactation.",{"count":51,"type":21},60,[53],"PHASE4","The goal of this clincal trial is to learn if doxapram is effective in weaning in adults on mechanical ventilation.\n\nThe objectives of this study:\n\n* Evaluate the effect of doxapram on diaphragmatic function (assessed by DE)during weaning from mechanical ventilation.\n* Assess the impact of doxapram on respiratory muscle sterngth.\n* Mointor adverse effects associated with doxapram administration.\n\nResearchers will compare expermental group(intervenous doxapram during weaning)with control group(saline infusion)during weaning.\n\nThe patients who fulfull criteria of weaning will be subjected to our clincal trial and put on spontanous breathing trial for 120mins using positive end expiratory pressure (peep)5 cmh2o,pressure support 5cm h2o and fio2 0.3.By the end of the SBTthe patient will be extubated if ventilator parameters and vital signs were maintained within 20%of baseline values.\n\nThe patients will be followed up after extubation and afailed weaning will be defined as the neeed for either invasive or non invasive ventilation for 72 after extubation or failed SBT.",[29,56],"Diaphragm Excursion","NOT_YET_RECRUITING","2026-06-05",{"date":60,"type":34},"2026-06-09",{"date":62,"type":21},"2026-06-01",{"date":64,"type":21},"2027-01-01",{"name":66,"class":67},"Kasr El Aini Hospital","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100637821","effectiveness-of-inspiratory-muscle-training-in-weaning-icu-patients-100637821","NCT07613021","Effectiveness of Inspiratory Muscle Training in Weaning ICU Patients","IMT in weaning","Inclusion Criteria:\n\n* ≥ 72h invasive mechanical ventilation\n* adequate co-operativeness as assessed by 5SQ ≥ 3.\n\nExclusion Criteria:\n\n* terminal condition or palliative care\n* neuromuscular or neurological conditions prior to ICU admission",{"count":76,"type":21},45,[24],"Patients in critical condition, due to their prolonged stay in the Intensive Care Unit (ICU), the severity of the underlying disease, and potential adverse effects of hospitalization, may develop serious complications, such as muscle atrophy and weakness, which also affect the respiratory muscles. It is characteristic that within the first 18-69 hours of mechanical ventilation (MV), proteolytic processes occur that lead to rapid atrophy of the diaphragm. Diaphragmatic dysfunction acquired during the ICU stay thus appears to have an adverse effect on weaning from mechanical ventilation, length of ICU stay, length of hospital stay, functional status, quality of life, and mortality within the ICU and the hospital. Inspiratory muscle training (IMT) has been identified as an intervention that could augment weaning, preventing the dedtrimental effects of MV. The purpose of this study is to assess the effect of an IMT protocol in weaning success of ICU patients. Specifically, an electronic device will be used that incorporates a tapered flow resistive technique.",[29],[81,82,83,84],"Inspiratory Muscle training","Weaning","Maximal Inspiratory pressure","Intensive Care Unit","2026-05-25",{"date":87,"type":34},"2026-05-29",{"date":89,"type":21},"2026-04",{"date":91,"type":21},"2029-12",{"name":93,"class":67},"University of West Attica",2,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":105,"conditions":106,"keywords":109,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100640506","phase-3-effect-of-remimazolam-sedation-on-outcomes-of-mechanically-ventilated-patients-in-the-icu-100640506","NCT07596589","Effect of Remimazolam Sedation on Outcomes of Mechanically Ventilated Patients in the ICU","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Endotracheal intubation and mechanical ventilation for 24-96 hours before enrollment Expected need for continued invasive ventilation and sedation for at least 24 hours;\n* Target sedation depth on the Richmond Agitation-Sedation Scale (RASS) between 0 and -3;\n* Informed consent obtained from the patient's family\n\nExclusion Criteria:\n\n* Body mass index (BMI) \\> 30 kg\u002Fm²\n* Severe central nervous system disease (e.g., acute stroke, uncontrolled seizures, or severe dementia) or any other condition that precludes RASS assessment\n* Mean arterial pressure (MAP) \\\u003C 55 mmHg despite intravenous fluid resuscitation and vasopressors\n* Heart rate \\\u003C 50 beats per minute, or second-degree or third-degree atrioventricular block in the absence of a pacemaker\n* Acute myocardial infarction or severe heart failure (New York Heart Association \\[NYHA\\] class IV)\n* Left ventricular ejection fraction \\\u003C 30%\n* Any contraindication or allergy to benzodiazepines\n* Substance dependence, alcohol abuse, or psychiatric\u002Fpsychological disorders. Alcohol abuse was defined as regular consumption of \\> 14 drinks per week (1 drink = 150 mL wine, 360 mL beer, or 45 mL liquor)\n* Acute hepatitis or severe hepatic dysfunction (Child-Pugh class C)\n* Chronic kidney disease with a glomerular filtration rate (GFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Neuromuscular disease\n* Patients on extracorporeal membrane oxygenation (ECMO)\n* Pregnancy or breastfeeding",{"count":102,"type":21},80,[104],"PHASE3","The goal of this clinical trial is to evaluate the effect of remimazolam sedation on outcomes of mechanically ventilated ICU patients through a single-center, prospective, randomized controlled, pilot study.",[107,29,108],"Remimazolam Besylate","Sedation",[110,111,112],"remimazolam","sedation","ICU","2026-05-18",{"date":115,"type":34},"2026-05-19",{"date":117,"type":34},"2025-04-01",{"date":119,"type":21},"2027-01-31",{"name":121,"class":67},"Southeast University, China",1]